What's Happening?
NHS England has commissioned a study to evaluate the effects of puberty blockers in children and young people with gender incongruence. The 'Pathways trial,' set to begin in January 2026, will involve
226 participants under 16 years old. The study aims to assess the impact of gonadotropin-releasing hormone analogues on quality of life, mental health, and physical health. Participants will be divided into two groups, with one starting treatment immediately and the other after 12 months. This trial follows a ban on puberty blockers for minors in the UK due to insufficient evidence on their effects.
Why It's Important?
The study is significant as it seeks to provide a clearer understanding of the benefits and risks associated with puberty blockers, which have been a contentious issue in gender identity treatment. The findings could influence future healthcare policies and practices regarding gender dysphoria treatment in minors. By conducting this trial, NHS England aims to address the lack of evidence and provide a scientific basis for the use of puberty blockers, potentially impacting the lives of children and young people experiencing gender incongruence.
